Aoquan

About Aoquan

Shanghai Auson Pharmaceuticals Co., Ltd. is a pharmaceutical company founded in 2019 by scientists with extensive experience in the pharmaceutical industry. The company operates internationally with an R&D center in Shanghai, China, responsible for research, manufacturing, clinical studies, and registration in China, and a subsidiary, Auson Pharmaceuticals Inc., in New Jersey, USA, which handles manufacturing, US registration, and commercialization.

Auson focuses on developing and commercializing drugs for vascular diseases and anti-viral applications to meet unmet medical needs in both Chinese and overseas markets. The business model centers on creating improved medicines by developing new dosage forms, new indications, and new dosing regimens for existing drugs. This strategy leverages abbreviated regulatory pathways, specifically the 505(b)(2) pathway in the U.S. and the Class 2 drug registration pathway in China, while also developing select niche generic products. The company's product pipeline includes ASN001 for infantile hemangioma, which has completed Phase I clinical trials in China, and ASN008, a once-weekly tablet for Hepatitis B that has completed Phase I trials in Australia. Another key product is ASN006, a new dosage form for treating and preventing venous thromboembolism, designed for patients who have difficulty swallowing.

The company was established by a team of senior researchers with backgrounds in both Chinese and American pharmaceutical R&D. Auson has secured significant funding to advance its pipeline, including a $5 million seed round from Kaitai Capital in 2019, a 65 million RMB Series A round, and a nearly 100 million RMB Series B round.